# Special Issue

# Antisense Therapy of Cancer

**Message from the Guest Editor**

Antisense and small interfering RNA (siRNA) therapies represents one of the most promising strategies in molecular oncology. These therapeutic approaches focus on the specific inhibition of gene expression responsible for tumor progression.

The potential of antisense oligonucleotides and siRNAs for genetic modulation has shown significant promise in preclinical and clinical studies. However, to maximize the efficacy and safety of these therapies, it is crucial that ongoing advancements are made in several areas. These include chemical modifications of oligonucleotides and siRNAs to improve their stability and activity, the development of efficient delivery systems for these therapeutic agents, and the optimization of their performance in vivo.

In this context, we invite researchers and scientists to contribute works exploring the latest advances in antisense therapy for cancer. We seek studies that delve into the evolution of chemical modifications that enhance the activity and stability of oligonucleotides, as well as new strategies for the efficient delivery of these therapeutic agents to tumor cells.

**Guest Editor**

Dr. Jaime E. Villegas

School of Veterinary Medicine, Faculty of Life Sciences, Universidad Andrés Bello, Santiago 8370251, Chile

**Deadline for manuscript submissions**

closed (20 February 2025)

GCAT
TACG
GCAT

**Genes**

**an Open Access Journal by MDPI**

**Impact Factor 2.8**
**CiteScore 5.5**
**Indexed in PubMed**

mdpi.com/si/213318

*Genes*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

# Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

# About the Journal

## Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

## Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

**Journal Rank:**

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))